Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 12 04:00PM ET
6.00
Dollar change
+0.35
Percentage change
6.19
%
Index- P/E- EPS (ttm)-2.70 Insider Own11.70% Shs Outstand43.40M Perf Week2.04%
Market Cap260.83M Forward P/E- EPS next Y-1.19 Insider Trans-0.16% Shs Float38.39M Perf Month6.95%
Income-71.03M PEG- EPS next Q-0.35 Inst Own67.34% Short Float6.46% Perf Quarter-6.25%
Sales0.00M P/S- EPS this Y34.86% Inst Trans-14.25% Short Ratio9.02 Perf Half Y21.21%
Book/sh1.05 P/B5.69 EPS next Y28.09% ROA-76.10% Short Interest2.48M Perf Year-3.23%
Cash/sh2.53 P/C2.37 EPS next 5Y46.23% ROE-209.50% 52W Range3.05 - 9.01 Perf YTD7.72%
Dividend Est.- P/FCF- EPS past 5Y38.92% ROI-112.07% 52W High-33.41% Beta1.78
Dividend TTM- Quick Ratio6.12 Sales past 5Y6.16% Gross Margin- 52W Low96.72% ATR (14)0.25
Dividend Ex-Date- Current Ratio6.12 EPS Y/Y TTM-12.27% Oper. Margin- RSI (14)61.19 Volatility4.69% 4.70%
Employees84 Debt/Eq0.50 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price15.90
Option/ShortYes / Yes LT Debt/Eq0.38 EPS Q/Q-31.89% Payout- Rel Volume1.35 Prev Close5.65
Sales Surprise-100.00% EPS Surprise-60.51% Sales Q/Q- EarningsNov 14 BMO Avg Volume274.91K Price6.00
SMA209.03% SMA505.10% SMA20011.74% Trades Volume371,525 Change6.19%
Date Action Analyst Rating Change Price Target Change
Jul-03-24Initiated H.C. Wainwright Buy $15
May-30-24Initiated Stifel Buy $21
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Feb-03-25 07:30AM
Dec-31-24 07:30AM
Dec-02-24 07:30AM
Nov-27-24 07:00AM
Nov-15-24 02:06AM
07:42AM Loading…
Nov-14-24 07:42AM
07:30AM
Nov-12-24 07:30AM
Nov-04-24 07:30AM
Nov-01-24 07:30AM
Oct-29-24 07:30AM
Oct-09-24 06:13PM
Oct-01-24 07:30AM
Sep-03-24 07:30AM
Sep-02-24 07:30AM
07:30AM Loading…
Aug-14-24 07:30AM
Aug-13-24 07:30AM
Aug-12-24 07:37AM
07:30AM
Aug-01-24 07:30AM
Jul-11-24 07:30AM
Jul-08-24 07:30AM
Jun-21-24 03:08AM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
02:17AM
May-15-24 12:53PM
07:43AM
07:30AM
07:30AM Loading…
May-07-24 07:30AM
May-03-24 11:19AM
07:30AM
Apr-23-24 02:04PM
08:53AM
07:39AM
07:09AM
Apr-22-24 05:58PM
04:27PM
04:14PM
04:05PM
Apr-01-24 08:30AM
Mar-19-24 06:53AM
05:31AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
07:30AM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
Nov-13-23 12:23PM
07:41AM
07:30AM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
07:30AM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
07:30AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
May-25-23 12:27AM
May-22-23 07:30AM
May-16-23 09:00AM
May-13-23 08:15AM
May-11-23 07:54AM
07:30AM
07:00AM
Apr-18-23 07:15AM
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
Nov-08-22 02:28PM
Nov-03-22 12:44PM
07:31AM
07:30AM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alvino MarkDirectorJan 29 '25Sale5.384,00021,52064,334Jan 31 04:30 PM
Alvino MarkOfficerJan 29 '25Proposed Sale5.414,00021,640Jan 29 04:03 PM
Alvino MarkDirectorJan 21 '25Sale5.104,00020,40068,334Jan 21 04:30 PM
Alvino MarkOfficerJan 21 '25Proposed Sale5.224,00020,880Jan 21 04:05 PM
Alvino MarkDirectorJun 18 '24Sale4.5125,890116,76436,926Jun 20 04:30 PM
Silverstein Christine BerniDirectorJun 18 '24Sale4.5125,821116,45362,063Jun 20 04:30 PM
Alland LeilaDirectorMay 16 '24Buy4.7111,00051,79982,857May 20 08:30 AM
Seshadri VishwasChief Executive OfficerApr 25 '24Buy3.2010,00032,000538,260Apr 29 08:30 AM
Charles Faith L.DirectorApr 26 '24Buy3.287,55024,76478,323Apr 29 08:30 AM
O'Malley Brendan M.SVP, General CounselApr 25 '24Buy3.248,60027,864188,718Apr 26 08:30 AM
Vazzano Joseph WalterChief Financial OfficerApr 25 '24Buy3.145,60817,609233,868Apr 26 08:30 AM